Recently, Muhammad et al. [9] enrolled 52 acromegaly patients that were considered partially resistant to first-gen SSA and proved that the reduction of IGF-I correlated positively with the expression of the subtype 2 of the somatostatin receptor (SSTR2). This evidence concerns the gene SSTR2 and acromegaly.